Lelystad, 6 July 2017 – Pepscan, the Dutch biotech company specialized in protein mimicry for the discovery of therapeutics peptides, announced today important progress with a drug development program based on its proprietary CLIPS technology. A team of Bicycle Therapeutics in the UK applied Pepscan’s CLIPS technology to identify a bicyclic CLIPS peptide that selectively binds to a protein (MT1-MMP) present on tumor cells. They subsequently linked a toxin payload to the high affinity bicyclic peptide, to create a ‘Bicycle …

Around 250 scientists convened on June 8 for the Dutch Peptide Symposium 2017, this time hosted by the Chemical Biology Department of TU Eindhoven. What originally started as an annual meeting of only Dutch scientists has now matured to an international symposium with participants from 15 different countries. Over 20 sponsors made this event possible through their financial support. This years’ meeting brought together scientists from academia and industry, and covered various aspects of peptide and protein chemistry as well …

Pepscan management and scientists regularly attend key industry conferences to meet customers and potential partners. This spring our CSO Peter Timmerman will be giving presentations about recent research work at various congresses, at which Pepscan will also be present with a booth. Drop by at our booth and meet our team this spring at: 13th German Peptide Symposium, 20-23 March 2017, Erlangen , Germany 20th GFPP Meeting  26-30 March 2017, Arcachon, France 4th Annual Peptides Congress, 24-25 April 2017, London UK …

Researchers of Pepscan have developed a peptide-based vaccine enabling a successful active anti-tumor immunization therapy targeting the growth hormone Vascular Endothelial Growth Factor (VEGF). The encouraging preclinical results have just been published in the reputable international journal PNAS (Proceedings of the National Academy of Sciences). VEGF is the pivotal growth factor for the formation of new blood vessels (angiogenesis). Targeting VEGF is a well established strategy to treat cancer, as demonstrated by the use of the monoclonal antibody bevacuzimab (Avastin®) …

As part of a tradition built by more than 20 successful Dutch Peptide Symposia, with gradually increasing numbers of participants from both academia and industry, Pepscan has the honor to host the 24th edition of the annual Dutch Peptide Symposium in 2016. We look forward to receive on 3 June, 2016 approximately 200 scientists in the novel Agora Congress Centre in Lelystad, the Netherlands. This meeting intends to cover the various aspects of peptide-, protein chemistry as well as drug discovery …

Lelystad, the Netherlands – October 15, 2015:  Pepscan Presto BV, a first class provider of custom peptide products and services for the life sciences industry, today announced that is has signed distribution agreement with Cosmo Bio Co., Ltd. of Tokyo, Japan. Cosmo Bio is a leading distributor of antibodies, enzymes, cell products, tissue culture materials and protein engineering products to universities, research institutes and pharma companies in Japan. Terms of the agreement were not disclosed. The distribution agreement will help …

Better access to a wealth of custom peptide-based products and services Lelystad, the Netherlands – August 21, 2015: Pepscan, a leading supplier of custom peptide-based products and services to the life sciences community, today announced the launch of their redesigned website (www.pepscan.com). With a new look and intuitive structure, it is organized to provide quicker and direct access to Pepscan’s broad portfolio of peptides and value-added services, such as Precision Epitope Mapping, its Custom Peptide Synthesis services and the PepChip …